Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has published its audited financial results for Q4 and FY ended March 31, 2026. Standalone total income declined to ₹567.55 Cr in Q4 FY26 from ₹768.57 Cr in Q4 FY25, while full-year income fell to ₹2,030.50 Cr from ₹2,504.43 Cr. Net profit after tax dropped significantly to ₹34.56 Cr for Q4 and ₹228.71 Cr for FY26, compared to ₹122.77 Cr and ₹491.18 Cr respectively in the prior year periods. Consolidated net profit after tax was ₹8.31 Cr for Q4 and ₹150.12 Cr for FY26. EPS (basic) fell to ₹0.90 for Q4 and ₹5.98 for FY26 from ₹3.22 and ₹12.89 in the prior year. The results were approved by the Board on May 12, 2026.
The company has reported a significant decline in both revenue and profitability year-over-year, which could be a concern for investors. The approximately 53% drop in standalone net profit and 69% drop in consolidated net profit signals material deterioration in financial performance.